NCR2 and graft versus host disease: Supporting this, appearance of IL-22-producing, gut-homing NKp44+ ILC3 in the blood of acute myeloid leukemia (AML) patients following conditioning treatment and hematopoetic stem cell transplantation (HSCT) is associated with protection against development of graft-versus-host disease (GVHD) [68].